Improved CRISPR-Cas9 genome editing tool

Rogier Louwen; J. van der Oost

Improved CRISPR-Cas9 genome editing tool

Rogier Louwen (Inventor), J. van der Oost (Inventor)

Research output: Patent

Abstract

The invention relates to a Cas-based, preferably Cas9-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cas9 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.

Original language	English
Patent number	WO2017155408
Priority date	11/03/16
Publication status	Published - 14 Sept 2017

Access to Document

https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=WO&NR=2017155408A1&KC=A1&FT=D&ND=3&date=20170914&DB=EPODOC&locale=en_EP

Cite this

@misc{80d8aa7b4d034d70ad77f00505d8dd2e,

title = "Improved CRISPR-Cas9 genome editing tool",

abstract = "The invention relates to a Cas-based, preferably Cas9-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cas9 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.",

author = "Rogier Louwen and {van der Oost}, J.",

year = "2017",

month = sep,

day = "14",

language = "English",

type = "Patent",

note = "WO2017155408",

}

TY - PAT

T1 - Improved CRISPR-Cas9 genome editing tool

AU - Louwen, Rogier

AU - van der Oost, J.

PY - 2017/9/14

Y1 - 2017/9/14

N2 - The invention relates to a Cas-based, preferably Cas9-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cas9 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.

AB - The invention relates to a Cas-based, preferably Cas9-based nuclease complex, wherein the guide RNA sequence is irreversibly crosslinked to the Cas9 protein. The cross-link may be a covalent binding or a non-covalent binding. Such a complex may be used in delivering constructs to a cell that are capable of gene-editing. Use of this cross-linked complex will result in less off-targeting.

M3 - Patent

M1 - WO2017155408

ER -

Improved CRISPR-Cas9 genome editing tool

Abstract

Access to Document

Fingerprint

Cite this